Newsfeeds - Spark Newswire

1 minute read

AbbVie-Roche’s Venclexta Shows Progression-Free Survival Of 74% In CLL Patients After Three Years Treatment

June 11, 10:11 AM

Genentech, a unit of Roche Holdings AG (OTC:RHHBY), and its collaborating partner AbbVie Inc (NYSE:ABBV) have announced long-term follow-up data from two Phase 3…

ABBV

1 minute read

Surface Oncology, Roche Team Up to Develop SRF388 Combo Therapy for Liver Cancer

By Vandana Singh

June 4, 10:04 AM

Surface Oncology (NASDAQ:SURF) has entered into a clinical trial collaboration with Roche Holdings AG (OTC:RHHBY) to evaluate former’s SRF388, anti-IL-27 antibody, in combination…

RHHBF

1 minute read

Uncategorized

Exelixis’ Cabometyx, Roche’s Tecentriq Combo Achieves 27% ORR in High-Risk Prostate Cancer Patients

By Vandana Singh

May 25, 7:48 AM

Exelixis Inc (NASDAQ: EXEL) has announced results from cohort 6 of the COSMIC-021 Phase 1b trial evaluating Cabometyx (cabozantinib) in combination with Roche’s Tecentriq (atezolizumab) in…

EXEL

1 minute read

Uncategorized

Prothena Receives $60M Milestone Payment After Parkinson’s Candidate Moves Forward In Mid-Stage Study With Dosing

By Vandana Singh

May 11, 6:57 AM

Prothena Corporation plc (NASDAQ: PRTA) has dosed the first patient in the Phase 2b PADOVA study evaluating prasinezumab in patients with early Parkinson’s disease.…

PRTA

Latest news

AbbVie-Roche’s Venclexta Shows Progression-Free Survival Of 74% In CLL Patients After Three Years Treatment

Surface Oncology, Roche Team Up to Develop SRF388 Combo Therapy for Liver Cancer

Exelixis’ Cabometyx, Roche’s Tecentriq Combo Achieves 27% ORR in High-Risk Prostate Cancer Patients

Prothena Receives $60M Milestone Payment After Parkinson’s Candidate Moves Forward In Mid-Stage Study With Dosing